Comparative Pharmacology
Head-to-head clinical analysis: CIALIS versus YESAFILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIALIS versus YESAFILI.
CIALIS vs YESAFILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
Selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing a conformational change leading to receptor degradation and inhibition of estrogen-dependent tumor growth.
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Terminal elimination half-life of 3–5 hours in healthy adults; prolonged in hepatic impairment (up to 8–10 hours), requiring dose adjustment.
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 2% of the dose, with biliary/fecal elimination as the major route.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor